Context Therapeutics Stock Target Price
| CNTX Stock | USD 1.56 0.04 2.63% |
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
Context | Target Price |
Context Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Context Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics of similar companies.Context Therapeutics is currently under evaluation in target price category among its peers.
Context Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 32.44 M | ||||
| Shares Outstanding | 75 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 76.40 % | ||||
| Number Of Shares Shorted | 879.63 K | ||||
| Price To Book | 1.40 X | ||||
| EBITDA | (25.06 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 42.92 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.64 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (21.05 M) | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Target Price | 7.7 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 117 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (68.05 M) | ||||
| Working Capital | 11.86 M | ||||
| Net Asset | 16.06 M |
About Context Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.